|
Schirdewan博士的引述的參考文獻:
' t4 r) b8 Q% n& |8 l1 L0 @% M/ [! Q1 A# s+ n
Camm, AJ et al., Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation (透過Home Monitoring技術遠距控制植入式裝置可改進房顫的檢測和臨床管理), Europace, 11(1):54–61, 2009. # C+ E( Q! Q" q! h: N6 B+ R/ x! B
6 S# E$ q) e7 ?2 g; ~7 e3 \8 jDaubert, JP et al., Inappropriate implantable cardioverter-defibrillator shocks in MADIT-II (MADIT-II中植入式心臟複律去顫器不合時宜的電擊), JACC, 51:1357–65, 2008 % r% _1 i5 g3 ^* e5 Z. ?; h [0 D
+ A' t; c9 @9 ~2 BRicci, RP et al., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (心房顫動管理指南:歐洲心臟學會心房顫動管理工作小組), Europace, 12(10):1360–1420, 2010.
" D0 u0 @5 e% [' ?
, w' E$ a4 j4 ?. |關於BIOTRONIK SE & Co. KG/ @# ^8 I% M" J
* q! ^6 n! m; R f" j2 u( X& ?BIOTRONIK公司是世界領先的心血管醫療器材製造商之一,已售出數百萬台植入式裝置,全球員工超過5600位,業務遍及100多個國家。BIOTRONIK公司密切感知醫療界的脈動、評估醫生面臨的挑戰,從診斷、治療到患者管理,為患者醫護的所有階段提供最佳解決方案。BIOTRONIK公司及其不斷成功的理念在於品質、創新和可靠性,從而為全球醫生及其患者帶來信心和安心。進一步資訊請瀏覽: www.biotronik.com |
|